KPV research guide
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone
A model-specific guide to KPV nomenclature and the mainly cellular and animal evidence surrounding this short alpha-MSH-derived tripeptide.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
KPV is the lysine-proline-valine C-terminal tripeptide of alpha-melanocyte-stimulating hormone and is also described as α-MSH (11-13). It should not be conflated with full-length alpha-MSH, Melanotan I or Melanotan II. Short sequences present distinct analytical challenges because related fragments can be difficult to distinguish without suitable mass and chromatographic methods.
02 · Evidence position
What the literature can support
The accessible research base is predominantly cell and animal work. Publications describing inflammatory signalling or experimental injury models are hypothesis-generating; they are not controlled evidence of a human therapeutic effect.
03 · Study-level map
Evidence and its limits
What cellular evidence exists?
A human dermal fibroblast study evaluated alpha-MSH-related peptides including a KPV-related sequence against TNF-alpha-stimulated signalling in vitro.
Limit: An isolated cell system cannot establish absorption, safety or efficacy in people.
What animal evidence exists?
A mouse traumatic-brain-injury experiment studied α-MSH (11-13) against histological and inflammatory outcomes.
Limit: The injury model and experimental exposure cannot be converted into a human-use claim or protocol.
04 · Analytical context
Questions a batch record should answer
- 01Does identity testing resolve KPV from closely related di- and tetrapeptide fragments?
- 02Are counter-ion, water content and net peptide content accounted for when reporting quantity?
- 03Is the method appropriate for a very short, highly polar tripeptide rather than copied from a larger peptide assay?
05 · Boundary conditions
What this record does not establish
- Robust controlled human evidence for KPV itself is not established by the cited studies.
- Results for full-length alpha-MSH or modified analogues should not be attributed automatically to KPV.
- This page describes evidence models and does not make an anti-inflammatory treatment claim.
Sources checked
- 1.Melanocyte stimulating hormone peptides inhibit TNF-alpha signalling in human dermal fibroblast cells
PubMed / Peptides · 2005 · Primary study
- 2.Tripeptide α-MSH (11-13) after experimental traumatic brain injury in mice
PubMed / PLOS ONE · 2013 · Primary study